MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Graham Jackson, Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, David A. Cairns, Gareth Morgan
Institutions: Newcastle University, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Leeds Teaching Hospitals NHS Trust, University of Leeds, Cancer Research UK Clinical Trials Unit, Brighton and Sussex Medical School, East Sussex Healthcare NHS Trust, University Hospital Southampton NHS Foundation Trust, University of Birmingham
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038466